Evidence map›Paper›PMID 22889954›Full record

ArticleJournal of hepatology2012

Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver.

Alessandro Furlan, Fabienne Lamballe, Venturina Stagni, Azeemudeen Hussain, Sylvie Richelme, Andrea Prodosmo, Anice Moumen, Christine Brun, Ivan Del Barco Barrantes, J Simon C Arthur and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Redundancy in the World of MAP Kinases: All for One.Frontiers in cell and developmental biology · 2016
    Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 5 countries.

Alessandro FurlanAix-Marseille Univ, IBDML, CNRS UMR 7288, Marseille, France.
Fabienne Lamballe
Venturina Stagni
Azeemudeen Hussain
Sylvie Richelme
Andrea Prodosmo
Anice Moumen
Christine Brun
Ivan Del Barco Barrantes
J Simon C Arthur
Anthony J Koleske
Angel R Nebreda
Daniela Barilà
Flavio Maina
Aix-Marseille Université · FRCentre National de la Recherche Scientifique · FRFondazione Santa Lucia · ITInstitució Catalana de Recerca i Estudis Avançats · ESInstitute for Research in Biomedicine · ESIstituti di Ricovero e Cura a Carattere Scientifico · ITMRC Protein Phosphorylation and Ubiquitylation Unit · GBYale University · US

Funding

Roles of Abl and Arg Neuronal DevelopmentR01NS039475 · NINDS · YALE UNIVERSITY · PI KOLESKE, ANTHONY J · 2000 to 2012
$4.3M
Supplement to Regulation of invadopodia formation in breast cancer cellsR01CA133346 · NCI · YALE UNIVERSITY · PI KOLESKE, ANTHONY J · 2009 to 2016
$2.3M
The mechanism of Arg kinase activation by integrin B1R01GM100411 · NIGMS · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON, KOLESKE, ANTHONY J · 2012 to 2015
$1.3M
NCI NIH HHS R01 CA133346NIGMS NIH HHS R01 GM100411NINDS NIH HHS R01 NS039475
6 · The paper itself

Abstract

BACKGROUND &

aimsGenetic studies indicate that distinct signaling modulators are each necessary but not individually sufficient for embryonic hepatocyte survival in vivo. Nevertheless, how signaling players are interconnected into functional circuits and how they coordinate the balance of cell survival and death in developing livers are still major unresolved issues. In the present study, we examined the modulation of the p53 pathway by HGF/Met in embryonic livers.

methodsWe combined pharmacological and genetic approaches to biochemically and functionally evaluate p53 pathway modulation in primary embryonic hepatocytes and in developing livers. RT-PCR arrays were applied to investigate the selectivity of p53 transcriptional response triggered by Met.

resultsMet recruits p53 to regulate the liver developmental program, by qualitatively modulating its transcriptional properties: turning on the Mdm2 survival gene, while keeping death and cell-cycle arrest genes Pmaip1 and p21 silent. We investigated the mechanism leading to p53 regulation by Met and found that Abl and p38MAPK are required for p53 phosphorylation on S(389), Mdm2 upregulation, and hepatocyte survival. Alteration of this signaling mechanism switches p53 properties, leading to p53-dependent cell death in embryonic livers. RT-PCR array studies affirmed the ability of the Met-Abl-p53 axis to modulate the expression of distinct genes that can be regulated by p53.

conclusionsA signaling circuit involving Abl and p38MAPK is required downstream of Met for the survival of embryonic hepatocytes, via qualitative regulation of the p53 transcriptional response, by switching its proapoptotic into survival properties.

Indexed as

Transcription, GeneticAnimalsCell SurvivalCyclin-Dependent Kinase Inhibitor p21HepatocytesLiverMicep38 Mitogen-Activated Protein KinasesPhosphorylationProto-Oncogene Proteins c-ablProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mdm2Proto-Oncogene Proteins c-metTumor Suppressor Protein p53Cyclin-Dependent Kinase Inhibitor p21p38 Mitogen-Activated Protein KinasesPmaip1 protein, mouseProto-Oncogene Proteins c-ablProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mdm2Proto-Oncogene Proteins c-metTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID22889954
PMCPMC3571726
OpenAlexW2106711839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.